Breaking the 90-Gene Barrier: The Infrastructure Play Behind Celliaz and Andelyn's Retinal Therapy Pact

COLUMBUS, Ohio – November 12, 2026 — For institutional investors and healthcare asset managers navigating the complex cell and gene therapy (CGT) landscape, the underlying manufacturing infrastructure is rapidly becoming as critical as the clinical science itself. The "picks and shovels" of the biotech gold rush are the Contract Development and Manufacturing Organizations (CDMOs) that de-risk the journey from the laboratory bench to the commercial market. This dynamic was brought into sharp focus today with the announcement of a strategic cross-border partnership between Columbus-based Andelyn Biosciences and South Korean biotechnology firm Celliaz Co., Ltd.

The agreement tasks Andelyn with the end-to-end development and manufacturing of CLZ002, an investigational adeno-associated virus (AAV)-based gene therapy aimed at treating retinitis pigmentosa (RP). Utilizing its proprietary AAV Curator® Suspension Platform, Andelyn will produce the AAV2 vectors and plasmids necessary to support Investigational New Drug (IND)-enabling studies and a planned Phase 1/2 clinical trial. Beyond the immediate clinical implications, this collaboration highlights two major trends shaping biotech investment strategies: the pivot toward gene-agnostic therapeutics to expand Total Addressable Markets (TAM), and the increasing reliance of international biotech innovators on specialized, FDA-compliant US manufacturing infrastructure.

Rethinking the Addressable Market: The Gene-Agnostic Shift

Retinitis pigmentosa represents a significant area of unmet medical need, affecting more than 3 million people worldwide and causing progressive vision loss. For years, the primary challenge for drug developers and their financial backers has been the extreme genetic heterogeneity of the disease. RP can result from mutations in more than 90 distinct genes.

The current standard-bearer in the space, Luxturna, was hailed as a medical breakthrough upon its approval. However, because it specifically targets patients with confirmed biallelic RPE65 gene mutations, its commercial reach is fundamentally limited to roughly one to two percent of the total RP patient population. For asset managers modeling long-term revenue potential, therapies tethered to single micro-populations present challenging economics.

Celliaz's CLZ002 represents a paradigm shift toward a gene-agnostic approach, aiming to treat the condition regardless of the underlying genetic mutation. Spun out of pioneering research from the Korea Advanced Institute of Science and Technology (KAIST), the therapy targets the PROX1 protein. In mammalian retinas, the transfer of PROX1 from neighboring cells into Müller glia suppresses the glia's natural regenerative activity. By blocking this intercellular transfer, CLZ002 is designed to unlock the latent regenerative capacity of the Müller glia, prompting them to adopt a progenitor-like state and replace damaged retinal neurons.

"RP can result from mutations in more than 90 genes, making it challenging to develop gene-specific therapies that benefit a broad patient population," said Kyung Hwa Kang, PhD, Chief Executive Officer of Celliaz. "CLZ002 represents a fundamentally different approach. Rather than targeting individual disease-causing mutations, our therapy aims to restore the retina's intrinsic regenerative capacity by preventing PROX1 transfer into Müller glia. These retinal cells retain latent regenerative potential. This gene-agnostic strategy could potentially benefit patients with RP caused by a wide range of genetic mutations. To translate this innovative approach into a clinical therapy, we needed a partner with strong scientific expertise and reliable manufacturing capabilities. Andelyn's extensive experience in ophthalmic and rare disease AAV programs, its Curator® Suspension Platform, and its integrated plasmid and viral vector manufacturing capabilities make it an ideal partner. We believe this partnership will be instrumental in advancing CLZ002 through IND-enabling development and toward our planned Phase 1/2 clinical trial."

This shift from mutation-specific replacement to broad-spectrum regeneration fundamentally alters the commercial calculus, potentially opening the door to a vastly expanded patient demographic and offering a more scalable asset for institutional portfolios.

The "Picks and Shovels" of Biotech: US CDMOs Fueling Global Pipelines

Transforming a novel biological mechanism into a viable clinical product requires highly specialized, capital-intensive manufacturing capabilities. The partnership between Celliaz and Andelyn underscores a vital geopolitical and supply chain strategy: international biotechs are increasingly turning to established US-based CDMOs to secure FDA-ready clinical supply and navigate stringent regulatory pathways.

Andelyn Biosciences, an FDA-inspected commercial-stage CDMO, operates from state-of-the-art facilities in Columbus, Ohio. With over two decades of experience, the organization has produced clinical and commercial material for more than 500 cGMP batches across 85 global clinical trials. Crucially for investors monitoring execution risk, Andelyn's Curator® Platform has a validated track record of regulatory acceptance, having been utilized to manufacture an FDA-approved AAV gene therapy for commercial supply.

"RP remains an area of significant unmet need, and Celliaz's approach is compelling," said Matt Niloff, Chief Commercial Officer at Andelyn Biosciences. "Andelyn supports client INDs with deep AAV expertise including ophthalmology and rare disease programs, and this relationship with Celliaz adds to our work supporting multiple other South Korean programs. We are proud to bring that experience, together with our Curator® Platform, to help Celliaz bring CLZ002 to the clinic."

Market analysts focused on biotech infrastructure note that CDMOs with scalable, cGMP-compliant suspension capabilities are becoming critical bottlenecks in the gene therapy sector. By securing capacity with Andelyn, Celliaz effectively mitigates one of the most significant risks in advanced therapy development: manufacturing failure. For South Korean biotechs, which are heavily supported by domestic venture capital and government grants, bridging the gap to the US market via partnerships with proven American CDMOs is a highly effective strategy to enhance global valuation and attract late-stage institutional capital.

Competitive Dynamics in the Retinal Pipeline

As Celliaz advances CLZ002 toward the clinic, it enters a rapidly evolving competitive landscape that is increasingly bifurcated between mutation-specific and mutation-agnostic strategies. Institutional investors are closely monitoring these competing modalities to determine which will capture the lion's share of the ophthalmology market.

On the mutation-specific front, therapies like Beacon Therapeutics' laru-zova (targeting X-linked RP caused by the RPGR gene) have shown strong late-stage clinical data, with regulatory submissions imminent. While these therapies offer high efficacy for specific cohorts, their market ceilings are inherently capped by genetics.

Conversely, the gene-agnostic space is gaining immense momentum. Nanoscope Therapeutics' MOGENRY, an optogenetic therapy designed to activate retinal bipolar cells regardless of the causative gene, is currently under FDA review with a decision expected in early 2027. Similarly, Ocugen's OCU400, a modifier gene therapy, is progressing through late-stage trials.

Celliaz's approach differentiates itself even within the gene-agnostic category. Rather than bypassing damaged photoreceptors with optogenetics or modifying cellular homeostasis, CLZ002 aims for true endogenous regeneration. Biopharma investment strategists point out that if Celliaz can demonstrate sustained, long-term regeneration in human trials without adverse gliosis, it could disrupt the current therapeutic hierarchy. However, the translation of Müller glia dedifferentiation from animal models to humans remains a complex biological hurdle that will require rigorous clinical validation.

Navigating the Clinical and Regulatory Horizon

The immediate focus for the Andelyn and Celliaz alliance is the successful execution of IND-enabling studies. The production of high-quality AAV2 vectors and engineered plasmids at Andelyn's Ohio facilities will form the backbone of the data package submitted to regulatory authorities.

The transition toward a Phase 1/2 clinical trial will be a critical value inflection point for Celliaz and a key test of Andelyn's Curator® Platform in delivering consistent, scalable yields for a novel regenerative asset. As the cell and gene therapy sector matures, the integration of cutting-edge scientific discovery with robust, commercial-grade manufacturing infrastructure is no longer an afterthought—it is a prerequisite for success. For the financial markets and institutional stakeholders observing this space, partnerships like the one forged today in Columbus provide a clear blueprint for how the next generation of breakthrough therapies will be built, scaled, and ultimately delivered to patients worldwide.